Clinical trial NCT00074373 - References

Systemic Lupus Erythematosus — The Research Registry for Neonatal Lupus

Citation(s)

•   Alvarez D, Briassouli P, Clancy RM, Zavadil J, Reed JH, Abellar RG, Halushka M, Fox-Talbot K, Barrat FJ, Buyon JP
  A novel role of endothelin-1 in linking Toll-like receptor 7-mediated inflammation to fibrosis in congenital heart block. J Biol Chem. 2011 Sep 2;286(35):30444-30454. doi: 10.1074/jbc.M111.263657. Epub 2011 Jul 5.
•   Askanase AD, Friedman DM, Copel J, Dische MR, Dubin A, Starc TJ, Katholi MC, Buyon JP
  Spectrum and progression of conduction abnormalities in infants born to mothers with anti-SSA/Ro-SSB/La antibodies. Lupus. 2002;11(3):145-51. doi: 10.1191/0961203302lu173oa.
•   Askanase AD, Iloh I, Buyon JP
  Hypothyroidism and antithyroglobulin and antithyroperoxidase antibodies in the pathogenesis of autoimmune associated congenital heart block. J Rheumatol. 2006 Oct;33(10):2099. No abstract available.
•   Askanase AD, Izmirly PM, Katholi M, Mumtaz J, Buyon JP
  Frequency of neuro-psychiatric dysfunction in anti-SSA/SSB exposed children with and without neonatal lupus. Lupus. 2010 Mar;19(3):300-6. doi: 10.1177/0961203309354542. Epub 2009 Dec 14.
•   Askanase AD, Miranda-Carus ME, Tang X, Katholi M, Buyon JP
  The presence of IgG antibodies reactive with components of the SSA/Ro-SSB/La complex in human breast milk: implications in neonatal lupus. Arthritis Rheum. 2002 Jan;46(1):269-71. doi: 10.1002/1529-0131(200201)46:13.0.CO;2-6. No abstract available.
•   Bachmann MP, Bartsch H, Gross JK, Maier SM, Gross TF, Workman JL, James JA, Farris AD, Jung B, Franke C, Conrad K, Schmitz M, Buttner C, Buyon JP, Semsei I, Harley JB, Rieber EP
  Autoimmunity as a result of escape from RNA surveillance. J Immunol. 2006 Aug 1;177(3):1698-707. doi: 10.4049/jimmunol.177.3.1698.
•   Briassouli P, Komissarova EV, Clancy RM, Buyon JP
  Role of the urokinase plasminogen activator receptor in mediating impaired efferocytosis of anti-SSA/Ro-bound apoptotic cardiocytes: Implications in the pathogenesis of congenital heart block. Circ Res. 2010 Aug 6;107(3):374-87. doi: 10.1161/CIRCRESAHA.109.213629. Epub 2010 Jun 17.
•   Briassouli P, Rifkin D, Clancy RM, Buyon JP
  Binding of anti-SSA antibodies to apoptotic fetal cardiocytes stimulates urokinase plasminogen activator (uPA)/uPA receptor-dependent activation of TGF-beta and potentiates fibrosis. J Immunol. 2011 Nov 15;187(10):5392-401. doi: 10.4049/jimmunol.1101288. Epub 2011 Oct 17.
•   Buyon JP, Askanase AD, Kim MY, Copel JA, Friedman DM
  Identifying an early marker for congenital heart block: when is a long PR interval too long? Comment on the article by Sonesson et al. Arthritis Rheum. 2005 Apr;52(4):1341-2. doi: 10.1002/art.20971. No abstract available.
•   Buyon JP, Brucato A, Friedman DM
  What's in a name? Ann Rheum Dis. 2008 May;67(5):732; discussion 732. doi: 10.1136/ard.2007.082693. No abstract available.
•   Buyon JP, Clancy RM, Friedman DM
  Autoimmune associated congenital heart block: integration of clinical and research clues in the management of the maternal / foetal dyad at risk. J Intern Med. 2009 Jun;265(6):653-62. doi: 10.1111/j.1365-2796.2009.02100.x.
•   Buyon JP, Clancy RM, Friedman DM
  Cardiac manifestations of neonatal lupus erythematosus: guidelines to management, integrating clues from the bench and bedside. Nat Clin Pract Rheumatol. 2009 Mar;5(3):139-48. doi: 10.1038/ncprheum1018.
•   Buyon JP, Clancy RM
  Autoantibody-associated congenital heart block: TGFbeta and the road to scar. Autoimmun Rev. 2005 Jan;4(1):1-7. doi: 10.1016/j.autrev.2004.04.003.
•   Buyon JP, Clancy RM
  Dying right to live longer: positing apoptosis as a link between maternal autoantibodies and congenital heart block. Lupus. 2008 Feb;17(2):86-90. doi: 10.1177/0961203307085115.
•   Buyon JP, Clancy RM
  Neonatal lupus: basic research and clinical perspectives. Rheum Dis Clin North Am. 2005 May;31(2):299-313, vii. doi: 10.1016/j.rdc.2005.01.010.
•   Buyon JP, Clancy RM
  Neonatal lupus: review of proposed pathogenesis and clinical data from the US-based Research Registry for Neonatal Lupus. Autoimmunity. 2003 Feb;36(1):41-50. doi: 10.1080/0891693031000067340.
•   Buyon JP, Hiebert R, Copel J, Craft J, Friedman D, Katholi M, Lee LA, Provost TT, Reichlin M, Rider L, Rupel A, Saleeb S, Weston WL, Skovron ML
  Autoimmune-associated congenital heart block: demographics, mortality, morbidity and recurrence rates obtained from a national neonatal lupus registry. J Am Coll Cardiol. 1998 Jun;31(7):1658-66. doi: 10.1016/s0735-1097(98)00161-2.
•   Buyon JP, Rupel A, Clancy RM
  Neonatal lupus syndromes. Lupus. 2004;13(9):705-12. doi: 10.1191/0961203304lu2008oa.
•   Buyon JP
  Updates on lupus and pregnancy. Bull NYU Hosp Jt Dis. 2009;67(3):271-5.
•   Cherian TS, Kariuki SN, Franek BS, Buyon JP, Clancy RM, Niewold TB
  Brief Report: IRF5 systemic lupus erythematosus risk haplotype is associated with asymptomatic serologic autoimmunity and progression to clinical autoimmunity in mothers of children with neonatal lupus. Arthritis Rheum. 2012 Oct;64(10):3383-7. doi: 10.1002/art.34571.
•   Clancy RM, Alvarez D, Komissarova E, Barrat FJ, Swartz J, Buyon JP
  Ro60-associated single-stranded RNA links inflammation with fetal cardiac fibrosis via ligation of TLRs: a novel pathway to autoimmune-associated heart block. J Immunol. 2010 Feb 15;184(4):2148-55. doi: 10.4049/jimmunol.0902248. Epub 2010 Jan 20.
•   Clancy RM, Backer CB, Yin X, Chang MW, Cohen SR, Lee LA, Buyon JP
  Genetic association of cutaneous neonatal lupus with HLA class II and tumor necrosis factor alpha: implications for pathogenesis. Arthritis Rheum. 2004 Aug;50(8):2598-603. doi: 10.1002/art.20442.
•   Clancy RM, Buyon JP, Ikeda K, Nozawa K, Argyle DA, Friedman DM, Chan EK
  Maternal antibody responses to the 52-kd SSA/RO p200 peptide and the development of fetal conduction defects. Arthritis Rheum. 2005 Oct;52(10):3079-86. doi: 10.1002/art.21289.
•   Clancy RM, Buyon JP
  Autoimmune-associated congenital heart block: dissecting the cascade from immunologic insult to relentless fibrosis. Anat Rec A Discov Mol Cell Evol Biol. 2004 Oct;280(2):1027-35. doi: 10.1002/ar.a.20072.
•   Clancy RM, Buyon JP
  More to death than dying: apoptosis in the pathogenesis of SSA/Ro-SSB/La-associated congenital heart block. Rheum Dis Clin North Am. 2004 Aug;30(3):589-602, x. doi: 10.1016/j.rdc.2004.04.013.
•   Clancy RM, Kapur RP, Molad Y, Askanase AD, Buyon JP
  Immunohistologic evidence supports apoptosis, IgG deposition, and novel macrophage/fibroblast crosstalk in the pathologic cascade leading to congenital heart block. Arthritis Rheum. 2004 Jan;50(1):173-82. doi: 10.1002/art.11430.
•   Clancy RM, Marion MC, Kaufman KM, Ramos PS, Adler A; International Consortium on Systemic Lupus Erythematosus Genetics; Harley JB, Langefeld CD, Buyon JP
  Identification of candidate loci at 6p21 and 21q22 in a genome-wide association study of cardiac manifestations of neonatal lupus. Arthritis Rheum. 2010 Nov;62(11):3415-24. doi: 10.1002/art.27658.
•   Clancy RM, Neufing PJ, Zheng P, O'Mahony M, Nimmerjahn F, Gordon TP, Buyon JP
  Impaired clearance of apoptotic cardiocytes is linked to anti-SSA/Ro and -SSB/La antibodies in the pathogenesis of congenital heart block. J Clin Invest. 2006 Sep;116(9):2413-22. doi: 10.1172/JCI27803. Epub 2006 Aug 10.
•   Clancy RM, Zheng P, O'Mahony M, Izmirly P, Zavadil J, Gardner L, Buyon JP
  Role of hypoxia and cAMP in the transdifferentiation of human fetal cardiac fibroblasts: implications for progression to scarring in autoimmune-associated congenital heart block. Arthritis Rheum. 2007 Dec;56(12):4120-31. doi: 10.1002/art.23061.
•   Friedman DM, Kim MY, Copel JA, Davis C, Phoon CK, Glickstein JS, Buyon JP; PRIDE Investigators
  Utility of cardiac monitoring in fetuses at risk for congenital heart block: the PR Interval and Dexamethasone Evaluation (PRIDE) prospective study. Circulation. 2008 Jan 29;117(4):485-93. doi: 10.1161/CIRCULATIONAHA.107.707661. Epub 2008 Jan 14.
•   Friedman DM, Kim MY, Copel JA, Llanos C, Davis C, Buyon JP
  Prospective evaluation of fetuses with autoimmune-associated congenital heart block followed in the PR Interval and Dexamethasone Evaluation (PRIDE) Study. Am J Cardiol. 2009 Apr 15;103(8):1102-6. doi: 10.1016/j.amjcard.2008.12.027. Epub 2009 Mar 4.
•   Friedman DM, Llanos C, Izmirly PM, Brock B, Byron J, Copel J, Cummiskey K, Dooley MA, Foley J, Graves C, Hendershott C, Kates R, Komissarova EV, Miller M, Pare E, Phoon CK, Prosen T, Reisner D, Ruderman E, Samuels P, Yu JK, Kim MY, Buyon JP
  Evaluation of fetuses in a study of intravenous immunoglobulin as preventive therapy for congenital heart block: Results of a multicenter, prospective, open-label clinical trial. Arthritis Rheum. 2010 Apr;62(4):1138-46. doi: 10.1002/art.27308.
•   Friedman DM, Rupel A, Buyon JP
  Epidemiology, etiology, detection, and treatment of autoantibody-associated congenital heart block in neonatal lupus. Curr Rheumatol Rep. 2007 May;9(2):101-8. doi: 10.1007/s11926-007-0003-4.
•   Glickstein J, Buyon J, Kim M, Friedman D; PRIDE investigators
  The fetal Doppler mechanical PR interval: a validation study. Fetal Diagn Ther. 2004 Jan-Feb;19(1):31-4. doi: 10.1159/000074256.
•   Gordon P, Khamashta MA, Rosenthal E, Simpson JM, Sharland G, Brucato A, Franceschini F, De Bosschere K, Meheus L, Meroni PL, Hughes GR, Buyon J
  Anti-52 kDa Ro, anti-60 kDa Ro, and anti-La antibody profiles in neonatal lupus. J Rheumatol. 2004 Dec;31(12):2480-7.
•   Hu K, Qu Y, Yue Y, Boutjdir M
  Functional basis of sinus bradycardia in congenital heart block. Circ Res. 2004 Mar 5;94(4):e32-8. doi: 10.1161/01.RES.0000121566.01778.06. Epub 2004 Feb 12.
•   Izmirly PM, Buyon JP, Saxena A
  Neonatal lupus: advances in understanding pathogenesis and identifying treatments of cardiac disease. Curr Opin Rheumatol. 2012 Sep;24(5):466-72. doi: 10.1097/BOR.0b013e328356226b.
•   Izmirly PM, Llanos C, Lee LA, Askanase A, Kim MY, Buyon JP
  Cutaneous manifestations of neonatal lupus and risk of subsequent congenital heart block. Arthritis Rheum. 2010 Apr;62(4):1153-7. doi: 10.1002/art.27333.
•   Izmirly PM, Rivera TL, Buyon JP
  Neonatal lupus syndromes. Rheum Dis Clin North Am. 2007 May;33(2):267-85, vi. doi: 10.1016/j.rdc.2007.02.005.
•   Izmirly PM, Saxena A, Kim MY, Wang D, Sahl SK, Llanos C, Friedman D, Buyon JP
  Maternal and fetal factors associated with mortality and morbidity in a multi-racial/ethnic registry of anti-SSA/Ro-associated cardiac neonatal lupus. Circulation. 2011 Nov 1;124(18):1927-35. doi: 10.1161/CIRCULATIONAHA.111.033894. Epub 2011 Oct 3.
•   Kamel R, Eftekhari P, Clancy R, Buyon JP, Hoebeke J
  Autoantibodies against the serotoninergic 5-HT4 receptor and congenital heart block: a reassessment. J Autoimmun. 2005 Aug;25(1):72-6. doi: 10.1016/j.jaut.2005.04.005.
•   Karnabi E, Qu Y, Wadgaonkar R, Mancarella S, Yue Y, Chahine M, Clancy RM, Buyon JP, Boutjdir M
  Congenital heart block: identification of autoantibody binding site on the extracellular loop (domain I, S5-S6) of alpha(1D) L-type Ca channel. J Autoimmun. 2010 Mar;34(2):80-6. doi: 10.1016/j.jaut.2009.06.005. Epub 2009 Jul 28.
•   Llanos C, Chan EK, Li S, Abadal GX, Izmirly P, Byrne C, Clancy RM, Buyon JP
  Antibody reactivity to alpha-enolase in mothers of children with congenital heart block. J Rheumatol. 2009 Mar;36(3):565-9. doi: 10.3899/jrheum.080860. Epub 2009 Feb 4.
•   Llanos C, Izmirly PM, Katholi M, Clancy RM, Friedman DM, Kim MY, Buyon JP
  Recurrence rates of cardiac manifestations associated with neonatal lupus and maternal/fetal risk factors. Arthritis Rheum. 2009 Oct;60(10):3091-7. doi: 10.1002/art.24768.
•   Martin V, Lee LA, Askanase AD, Katholi M, Buyon JP
  Long-term followup of children with neonatal lupus and their unaffected siblings. Arthritis Rheum. 2002 Sep;46(9):2377-83. doi: 10.1002/art.10638.
•   Neiman AR, Lee LA, Weston WL, Buyon JP
  Cutaneous manifestations of neonatal lupus without heart block: characteristics of mothers and children enrolled in a national registry. J Pediatr. 2000 Nov;137(5):674-80. doi: 10.1067/mpd.2000.109108.
•   Neufing PJ, Clancy RM, Jackson MW, Tran HB, Buyon JP, Gordon TP
  Exposure and binding of selected immunodominant La/SSB epitopes on human apoptotic cells. Arthritis Rheum. 2005 Dec;52(12):3934-42. doi: 10.1002/art.21486.
•   Niewold TB, Rivera TL, Buyon JP, Crow MK
  Serum type I interferon activity is dependent on maternal diagnosis in anti-SSA/Ro-positive mothers of children with neonatal lupus. Arthritis Rheum. 2008 Feb;58(2):541-6. doi: 10.1002/art.23191.
•   Ramos PS, Marion MC, Langefeld CD; International Consortium on Systemic Lupus Erythematosus Genetics; Buyon JP, Clancy RM
  Brief report: enrichment of associations in genes with fibrosis, apoptosis, and innate immunity functions with cardiac manifestations of neonatal lupus. Arthritis Rheum. 2012 Dec;64(12):4060-5. doi: 10.1002/art.34663.
•   Reed JH, Clancy RM, Lee KH, Saxena A, Izmirly PM, Buyon JP
  Umbilical cord blood levels of maternal antibodies reactive with p200 and full-length Ro 52 in the assessment of risk for cardiac manifestations of neonatal lupus. Arthritis Care Res (Hoboken). 2012 Sep;64(9):1373-81. doi: 10.1002/acr.21704.
•   Reed JH, Clancy RM, Purcell AW, Kim MY, Gordon TP, Buyon JP
  beta2-glycoprotein I and protection from anti-SSA/Ro60-associated cardiac manifestations of neonatal lupus. J Immunol. 2011 Jul 1;187(1):520-6. doi: 10.4049/jimmunol.1100122. Epub 2011 May 20.
•   Reed JH, Jain M, Lee K, Kandimalla ER, Faridi MH, Buyon JP, Gupta V, Clancy RM
  Complement receptor 3 influences toll-like receptor 7/8-dependent inflammation: implications for autoimmune diseases characterized by antibody reactivity to ribonucleoproteins. J Biol Chem. 2013 Mar 29;288(13):9077-83. doi: 10.1074/jbc.M112.403303. Epub 2013 Feb 5.
•   Reynolds HR, Buyon J, Kim M, Rivera TL, Izmirly P, Tunick P, Clancy RM
  Association of plasma soluble E-selectin and adiponectin with carotid plaque in patients with systemic lupus erythematosus. Atherosclerosis. 2010 Jun;210(2):569-74. doi: 10.1016/j.atherosclerosis.2009.12.007. Epub 2009 Dec 16.
•   Rivera TL, Izmirly PM, Birnbaum BK, Byrne P, Brauth JB, Katholi M, Kim MY, Fischer J, Clancy RM, Buyon JP
  Disease progression in mothers of children enrolled in the Research Registry for Neonatal Lupus. Ann Rheum Dis. 2009 Jun;68(6):828-35. doi: 10.1136/ard.2008.088054. Epub 2008 Jul 14.
•   Routsias JG, Kyriakidis NC, Friedman DM, Llanos C, Clancy R, Moutsopoulos HM, Buyon J, Tzioufas AG
  Association of the idiotype:antiidiotype antibody ratio with the efficacy of intravenous immunoglobulin treatment for the prevention of recurrent autoimmune-associated congenital heart block. Arthritis Rheum. 2011 Sep;63(9):2783-9. doi: 10.1002/art.30464.
•   Saxena A, McDonnell E, Ramos PS, Sajuthi S, Marion MC, Langefeld CD, Buyon JP, Clancy RM
  Preferential transmission of genetic risk variants of candidate loci at 6p21 from asymptomatic grandparents to mothers of children with neonatal lupus. Arthritis Rheum. 2012 Mar;64(3):931-9. doi: 10.1002/art.33366.
•   Solomon DG, Rupel A, Buyon JP
  Birth order, gender and recurrence rate in autoantibody-associated congenital heart block: implications for pathogenesis and family counseling. Lupus. 2003;12(8):646-7. doi: 10.1191/0961203303lu425xx. No abstract available. Erratum In: Lupus. 2003;12(10):801.
•   Stea EA, Routsias JG, Clancy RM, Buyon JP, Moutsopoulos HM, Tzioufas AG
  Anti-La/SSB antiidiotypic antibodies in maternal serum: a marker of low risk for neonatal lupus in an offspring. Arthritis Rheum. 2006 Jul;54(7):2228-34. doi: 10.1002/art.21954.
•   Strandberg L, Winqvist O, Sonesson SE, Mohseni S, Salomonsson S, Bremme K, Buyon JP, Julkunen H, Wahren-Herlenius M
  Antibodies to amino acid 200-239 (p200) of Ro52 as serological markers for the risk of developing congenital heart block. Clin Exp Immunol. 2008 Oct;154(1):30-7. doi: 10.1111/j.1365-2249.2008.03732.x. Epub 2008 Aug 22.
•   Tran HB, Cavill D, Buyon JP, Gordon TP
  Intravenous immunoglobulin and placental transport of anti-Ro/La antibodies: comment on the letter by Kaaja and Julkunen. Arthritis Rheum. 2004 Jan;50(1):337-8; author reply 338. doi: 10.1002/art.11498. No abstract available.

The Research Registry for Neonatal Lupus

Details for clinical trial NCT00074373